Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J MacFadyen

Showing results (111-120 of 163) with videos related to

Pageof 17
Sort By:
American Heart Journal|September 1, 1993
Angiotensin-converting enzyme inhibitors in heart failure: blood pressure changes after the first doseJ L Reid, R J MacFadyen, I B Squire, et al.
Heart (British Cardiac Society)|October 20, 1999
Non-adherence with ACE inhibitor treatment is common in heart failure and can be detected by routine serum ACE activity assaysA D Struthers, G Anderson, R J MacFadyen, et al.
Congestive Heart Failure (Greenwich, Conn.)|February 6, 2002
Nonadherence with ACE inhibitors is common and can be detected in clinical practice by routine serum ACE activityA D Struthers, G Anderson, R J MacFadyen, et al.
Thrombosis Research|December 25, 2004
Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2Muzahir H Tayebjee, Gregory Y H Lip, Andrew D Blann, et al.
International Journal of Cardiology|January 18, 2006
Sudden death is less common than might be expected in underprivileged ethnic minorities at high cardiovascular riskAli Hamaad, Angie Ghattas, Fatima Hirani, et al.
Journal of Cardiovascular Pharmacology|July 1, 1996
Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete menM McIntyre, R J MacFadyen, P A Meredith, et al.
Thrombosis and Haemostasis|March 18, 2006
Abnormal circulating neutrophil linked matrix metalloproteinase -9 in stable coronary artery diseaseMuzahir H Tayebjee, Gregory Y H Lip, Kiat T Tan, et al.
The American Journal of Cardiology|July 16, 2005
Relation of platelet activation to coronary angiographic severity and collateralizationKiat T Tan, Muzahir H Tayebjee, Robert J Macfadyen, et al.
Journal of Internal Medicine|December 21, 2004
Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severityM H Tayebjee, K T Tan, R J MacFadyen, et al.
American Journal of Hypertension|September 15, 2004
Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxationMuzahir H Tayebjee, Sunil K Nadar, Robert J MacFadyen, et al.
Pageof 17

Showing results (111-120 of 163) with videos related to

Sort By:
Pageof 17
American Heart Journal|September 1, 1993
Angiotensin-converting enzyme inhibitors in heart failure: blood pressure changes after the first doseJ L Reid, R J MacFadyen, I B Squire, et al.
Heart (British Cardiac Society)|October 20, 1999
Non-adherence with ACE inhibitor treatment is common in heart failure and can be detected by routine serum ACE activity assaysA D Struthers, G Anderson, R J MacFadyen, et al.
Congestive Heart Failure (Greenwich, Conn.)|February 6, 2002
Nonadherence with ACE inhibitors is common and can be detected in clinical practice by routine serum ACE activityA D Struthers, G Anderson, R J MacFadyen, et al.
Thrombosis Research|December 25, 2004
Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2Muzahir H Tayebjee, Gregory Y H Lip, Andrew D Blann, et al.
International Journal of Cardiology|January 18, 2006
Sudden death is less common than might be expected in underprivileged ethnic minorities at high cardiovascular riskAli Hamaad, Angie Ghattas, Fatima Hirani, et al.
Journal of Cardiovascular Pharmacology|July 1, 1996
Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete menM McIntyre, R J MacFadyen, P A Meredith, et al.
Thrombosis and Haemostasis|March 18, 2006
Abnormal circulating neutrophil linked matrix metalloproteinase -9 in stable coronary artery diseaseMuzahir H Tayebjee, Gregory Y H Lip, Kiat T Tan, et al.
The American Journal of Cardiology|July 16, 2005
Relation of platelet activation to coronary angiographic severity and collateralizationKiat T Tan, Muzahir H Tayebjee, Robert J Macfadyen, et al.
Journal of Internal Medicine|December 21, 2004
Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severityM H Tayebjee, K T Tan, R J MacFadyen, et al.
American Journal of Hypertension|September 15, 2004
Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxationMuzahir H Tayebjee, Sunil K Nadar, Robert J MacFadyen, et al.
Pageof 17